Coexpression of ΔNp63/p40 and TTF1 Within Most of the Same Individual Cells Identifies Life-Threatening NSCLC Featuring Squamous and Glandular Biphenotypic Differentiation: Clinicopathologic Correlations [0.03%]
大多数相同的单个细胞共表达ΔNp63 / p40和TTF1，可识别具有鳞状和腺性双表型分化的致命NSCLC：临床病理相关性
Giuseppe Pelosi,Matteo Bulloni,Martina Vescio et al.
Giuseppe Pelosi et al.
Introduction: Double occurrence of TTF1 and ΔNp63/p40 (henceforth, p40) within the same individual cells is exceedingly rare in lung cancer. Little is known on their biological and clinical implications. ...
ALK Gene Rearrangements in Lung Adenocarcinomas: Concordance of Immunohistochemistry, Fluorescence In Situ Hybridization, RNA In Situ Hybridization, and RNA Next-Generation Sequencing Testing [0.03%]
肺腺癌中ALK基因重排：免疫组化、荧光原位杂交，RNA原位杂交和RNA下一代序列检测的一致性研究
Carleigh R Canterbury,Helen Fernandes,John P Crapanzano et al.
Carleigh R Canterbury et al.
Introduction: The 2018 updated molecular testing guidelines for patients with advanced lung cancer incorporated ALK immunohistochemistry (IHC) analysis as an equivalent to fluorescence in situ hybridization (FISH) method ...
Important Surgical and Clinical End Points in Neoadjuvant Immunotherapy Trials in Resectable NSCLC [0.03%]
可切除NSCLC新辅助免疫治疗试验中重要的外科和临床终点事件
Jay M Lee,Anthony W Kim,Tomasz Marjanski et al.
Jay M Lee et al.
Neoadjuvant immunotherapy may improve outcomes in patients with resectable NSCLC and is being evaluated in phase 2 and 3 studies. Nevertheless, preoperative treatment postpones resection; the potential for increased surgical complexity and ...
Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC [0.03%]
非小细胞肺癌中检查点抑制剂肺炎的前期肺功能研究
Joshua E Reuss,Emily Brigham,Kevin J Psoter et al.
Joshua E Reuss et al.
Introduction: Checkpoint inhibitor pneumonitis (CIP) is a serious toxicity of anti-programmed death-(ligand) 1 immunotherapy. Whether pretreatment differences in pulmonary function exist in patients who develop CIP is unk...
In Response to "Intratumor Distribution of Ki-67 Antigen Beyond Labeling Index for Clinical Decision Making: A New Way of Counting" [0.03%]
对“肿瘤内Ki-67抗原的分布超出标记指数用于临床决策：新的计数方式”的回应
Robert A Belderbos,Joachim G J V Aerts,Jan H von der Thüsen
Robert A Belderbos
Intratumor Distribution of Ki-67 Antigen Beyond Labeling Index for Clinical Decision-Making: A New Way of Counting [0.03%]
Ki-67抗原在肿瘤内的分布超越标记指数用于临床决策的新计数方式
Matteo Bulloni,Linda Pattini,Giuseppe Pelosi
Matteo Bulloni
Perspective on the Cardiotoxicity of Third-Generation Targeted EGFRs in the Treatment of NSCLC [0.03%]
第三代针对性EGFR治疗NSCLC的心脏毒性研究进展
Michael S Ewer,Steven M Ewer
Michael S Ewer
Phase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in BAP1 Gene [0.03%]
奥拉帕尼二期研究在恶性胸膜间皮瘤中以及疗效与BAP1基因种系或体系突变的相关性研究
Azam Ghafoor,Idrees Mian,Cathy Wagner et al.
Azam Ghafoor et al.
Introduction: PARP inhibition may enhance antitumor responses in BAP1-associated mesothelioma by inducing synthetic lethality. Methods: ...
Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous NSCLC in KEYNOTE-407 [0.03%]
派姆单抗联合化疗治疗KEYNOTE-407中的中国转移性鳞状NSCLC患者
Ying Cheng,Li Zhang,Jie Hu et al.
Ying Cheng et al.
Introduction: Pembrolizumab plus chemotherapy significantly improved survival outcomes versus placebo plus chemotherapy in patients with previously untreated metastatic squamous NSCLC in the randomized, double-blind, phas...
Comparison of Tumor Microenvironments Between Primary Tumors and Brain Metastases in Patients With NSCLC [0.03%]
NSCLC患者原发肿瘤和脑转移瘤的肿瘤微环境的比较
Daiki Ikarashi,Tamio Okimoto,Takehito Shukuya et al.
Daiki Ikarashi et al.
Introduction: This study investigates the immune profile of the primary lung tumors and the corresponding brain metastasis from patients with NSCLC using multiplex fluorescence immunohistochemistry. ...